References
- Davies H , BignellGR , CoxCet al. Mutations of the BRAF gene in human cancer . Nature417 , 949 – 954 ( 2002 ).
- Chapman PB , HauschildA , RobertCet al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation . N. Engl. J. Med.364 , 2507 – 2516 ( 2011 ).
- Flaherty KT , RobertC , HerseyPet al. Improved survival with MEK inhibition in BRAF-mutated melanoma . N. Engl. J. Med.367 , 107 – 114 ( 2012 ).
- Hauschild A , GrobJJ , DemidovLVet al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, Phase 3 randomized controlled trial . Lancet380 , 358 – 365 ( 2012 ).
- Ascierto PA , SchadendorfD , BerkingCet al. MEK162 for patients with advanced melanoma harboring NRAS or Val600 BRAF mutations: a non-randomized, open-label Phase 2 study . Lancet Oncol.14 , 249 – 256 ( 2013 ).
- Long GV , WilmottJS , CapperDet al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma . Am. J. Surg. Pathol.37 , 61 – 65 ( 2013 ).
- Busam KJ , HedvatC , PulitzerM , von DeimlingA , JungbluthAA . Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions . Am. J. Surg. Pathol.37 , 413 – 420 ( 2013 ).
- Feller JK , YangS , MahalingamM . Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma . Mod. Pathol.26 , 414 – 420 ( 2013 ).
- Lade-Keller J , KristensenLS , Riber-HansenRet al. A role for immunohistochemical detection of BRAF V600E prior to BRAF-inhibitor treatment of malignant melanoma? J. Clin. Pathol. 66 , 723 – 725 ( 2013 ).
- Wilmott JS , MenziesAM , HayduLEet al. BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma . Br. J. Cancer108 , 924 – 931 ( 2013 ).
- Pearlstein MV , ZedekDC , OllilaDWet al. Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma . J. Cutan. Pathol.41 , 724 – 732 ( 2014 ).
- Menzies AM , LumT , WilmottJSet al. Intrapatient homogeneity of BRAFV600E expression in melanoma . Am. J. Surg. Pathol.38 , 377 – 382 ( 2014 ).
- Boursault L1 , HaddadV , VergierBet al. Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing . PLoS ONE8 , e70826 ( 2013 ).
- Marin C , BeauchetA , CapperDet al. Detection of BRAF p. V600E mutations in melanoma by immunohistochemistry has a good interobserver reproducibility . Arch. Pathol. Lab. Med.138 , 71 – 75 ( 2014 ).
- Mandala M , MerelliB , MassiD . NRAS in melanoma: targeting the undruggable target . Crit. Rev. Oncol. Haematol.92 ( 2 ), 107 – 122 ( 2014 ).
- Jakob JA , BassettRLJr , NgCSet al. NRAS mutation status is an independent prognostic factor in metastatic melanoma . Cancer118 , 4014 – 4023 ( 2012 ).
- Massi D , SimiL , SensiEet al. Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma . Mod. Pathol. doi:10.1038/modpathol.137 ( 2014 ) ( Epub ahead of print ).
- Taylor CR . Predictive biomarkers and companion diagnostics. The future of immunohistochemistry: ‘in situ proteomics’, or just a ‘stain’?Appl. Immunohistochem. Mol. Morphol.22 , 555 – 561 ( 2014 ).
- Jiang X , ZhouJ , Giobbie-HurderA , WargoJ , HodiFS . The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition . Clin. Cancer Res.19 , 598 – 609 ( 2013 ).
- Taube JM , KleinA , BrahmerJRet al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy . Clin. Cancer Res.20 , 5064 – 5074 ( 2014 ).